P. Rougier

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

C. Köhne, J. Nippgen, P. Rougier, 2007 .

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

M. Büchler, J. Berlin, M. Hidalgo, 2014 .

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

Tumeurs desmoïdes ou fibromatoses intra-abdominales.

D. Élias, P. Lasser, G. Contesso, 1993 .

Progrès récents en chimiothérapie adjuvante des cancers du côlon

P. Rougier, M. Ducreux, P. Rougier, 1997 .

Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer

J. Tabernero, F. Lévi, P. Rougier, 2007 .